Intersect ENT, Inc. (NASDAQ: XENT) today announced presentation of a meta-analysis from two randomized studies evaluating the safety and efficacy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE